1. Home /
    2. Altai Protocol Library /
  2. New Drug – Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug – Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer

New Drug – Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
Study:
  • Open-label phase 1–2 trial
  • Previously platinum-based chemotherapy
  • Advanced or metastatic RET fusion positive NSCLC pts who had been treated with platinum (phase I: 49 pts) and who were untreated (phase II: 56 pts)
  • Selpercatinib 160 mg twice daily
Efficacy:
  • ORR: 64% (CR:2%, PR:62%, SD:29%)
  • DOR: 17.5 months
  • mPFS: 16.5 months
Safety:
  • Any grade AEs: 91%, dry mouth:36%, diarrhea:25%, AST elevation:30%
  • Any grade ≥3 AEs: Hypertension:14%, ALT elevation:13%, hyponatremia: 6%, lymphopenia:6%

N Engl J Med. 2020 Aug 27;383(9):813-824.

Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

https://doi.org/10.1056/nejmoa2005653

Reviewed by Hasan Çağrı Yıldırım, MD on Sep 27, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More